コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 microdilution, CLSI broth microdilution, and Etest).
2 ty testing for levofloxacin was performed by Etest.
3 d by broth microdilution, agar dilution, and Etest.
4 tested for mupirocin susceptibility by using Etest.
5 enerated by this method to MICs generated by Etest.
6 eillance were concurrently tested by BMD and Etest.
7 em, meropenem, and cefepime by utilizing the Etest.
8 es were also classified as nonsusceptible by Etest.
9 tories performed susceptibility testing with Etest.
10 etermined using the K-B diffusion method and eTest.
11 sk diffusion and 4 (13.3%) minor errors with Etest.
12 tion; mupirocin susceptibility was tested by Etest.
13 ibility by the disk-diffusion method and the Etest.
14 by broth macrodilution, disk diffusion, and Etest.
15 cessful transition from agar dilution to the Etest.
16 UC/MIC by broth microdilution and AUC/MIC by Etest.
17 = 0.25/0.5 mug/ml by broth microdilution and Etest.
18 and, in particular, to use caution with the Etest.
19 monly used antibiotics by disk diffusion and Etest.
20 isolates were interpreted as susceptible by Etest.
21 , five had susceptible MICs as determined by Etest.
22 (BMD-T), broth macrodilution (TDS), and the Etest.
23 on, broth microdilution, disk diffusion, and Etest.
24 ion (0.902, standard error [SE] = 0.076) and Etest (1.00, SE = 0.218) and for amphotericin B by disk
25 quent false-NS results (30 for BMD30, 18 for Etest, 22 for MicroScan Prompt, and 25 for MicroScan tur
27 ylococci were the highest for VITEK (35.7%), Etest (40.0%), and disk diffusion (53.3%), although the
28 63% (60/96) of isolates were susceptible by Etest, 70% (67/96) by DD, and 88% (84/96) by agar diluti
30 meropenem by agar dilution, disk diffusion, Etest (AB BIODISK North America, Inc., Piscataway, N.J.)
32 In this study, we found that the dalbavancin Etest (AB BIODISK, Solna, Sweden) procedure demonstrated
33 all 100 isolates were tested in parallel by Etest (AB Biodisk, Solna, Sweden), MicroScan WalkAway (D
35 ostics, Sparks, MD), oxacillin and cefoxitin Etests (AB Biodisk, Solna, Sweden) on Mueller-Hinton aga
36 s results from three validated methods (BMD, Etest [AB Biodisk, Solna, Sweden], and disk diffusion).
37 agar dilution method and, separately, by the Etest according to the manufacturer's recommendations.
38 ween broth microdilution (BMD), Vitek 2, and Etest against 48 clinical KPC-producing Klebsiella pneum
39 otic Susceptibility Testing (EUCAST) and the Etest agar diffusion method were compared with the Clini
43 tes were significantly lower than those from Etest analysis at the time of isolation for both antibio
45 erall categorical agreement (CA) was 90% for Etest and 88% for Sensititre; minor errors accounted for
50 ow (~51%) categorical agreement (CA) between Etest and BMD results across CLSI and EUCAST breakpoints
52 cy was noted between the results obtained by Etest and broth microdilution for voriconazole, the Etes
54 system (Vitek 2) and retrospective testing (Etest and CLSI reference broth microdilution [BMD] metho
55 .2% (micafungin), whereas the EA between the Etest and CLSI results ranged from 90.2% (caspofungin) t
57 is study was to determine the ability of the Etest and DD methods to differentiate daptomycin-suscept
64 glucose-6-phosphate-supplemented fosfomycin Etest and Kirby-Bauer disk diffusion (DD) assays, and th
66 Overall agreement percentages between the Etest and microdilution MICs were 97.6% for voriconazole
68 lity testing in our clinical laboratory, the Etest and Sensititre methods were compared with the Clin
69 ere determined after 48 h of incubation, and Etest and Sensititre MICs were determined after 24 h and
73 Where a discrepancy was observed between Etest and the reference method, the Etest MIC was genera
74 where a discrepancy was observed between the Etest and the reference method, the Etest MIC was lower.
75 Where a discrepancy was observed between Etest and the reference method, the Etest tended to give
76 Where a discrepancy was observed between Etest and the reference method, the Etest tended to give
77 blood culture bottles by disk diffusion and Etest and the results of standardized susceptibility tes
79 mpared posaconazole M27-A2 and M38-A MICs to Etest and YeastOne MICs for 92 zygomycetes, 126 Aspergil
82 medium supplementation (BMD30 method), (iii) Etest, and (iv and v) MicroScan panel 33 using 2 methods
87 R) were tested by broth microdilution (BMD), Etest, and disk diffusion (DD), and the modified Hodge t
90 nce method) for MicroScan, Phoenix, VITEK 2, Etest, and VITEK were 99.0%, 95.8%, 92.0%, 92.0%, and 85
91 l 2016 through 10 May 2016 underwent routine Etest antimicrobial susceptibility testing by the Hawaii
92 rodilution method, validating the use of the Etest as an alternative test for investigational or clin
93 amicin, and tobramycin using disk diffusion, Etest, as well as the Phoenix, Vitek 2, and MicroScan au
97 methods (agar dilution, broth microdilution, Etest at 0.5 and 2.0 McFarland (McF) inocula, two agar s
99 the MicroScan MICroSTREP plus (Siemens), and Etest (bioMerieux) for antibiotic susceptibility tests (
100 on (Mast Group Ltd., Bootle Merseyside, UK), Etest (bioMerieux, Inc., Durham, NC), and MIC test strip
105 ported to be elevated when determined by the Etest compared to determinations by the broth microdilut
106 s significantly more common as determined by Etest compared to that determined by BMD (odds ratio [OR
107 evaluation of the performance of the new P/T Etest compared to that of BMD following U.S. Food and Dr
108 luated the performance of disk diffusion and Etest compared to that of reference broth microdilution
110 , since MICs are significantly elevated with Etest compared to those determined by the three other me
115 used in clinical microbiology laboratories (Etest, disk diffusion, and Sensititre broth microdilutio
116 ade Behring, Inc., West Sacramento, Calif.), Etest ESBL (AB BIODISK, Piscataway, N.J.), Vitek GNS-120
118 firmation panel, 100%; VITEK 1 GNS-120, 99%; Etest ESBL, 97%; and BD BBL Sensi-Disk ESBL Confirmatory
123 der the supplemental use of reference BMD or Etest for cefepime and meropenem for susceptibility test
126 nts (CA) of Phoenix, Vitek 2, MicroScan, and Etest for penicillin were 95.5%, 94.2%, 98.7%, and 97.7%
128 - and intralaboratory reproducibility of the Etest for susceptibility testing of the rapidly growing
129 regarding the suitability of the tigecycline Etest for testing S. marcescens, Acinetobacter spp., and
134 c susceptibility testing reagents (including Etest) for fusidic acid (CEM-102) performed at an excell
135 sessing concomitant ESBL and pAmpC genes for Etest (four of five), BD Phoenix (three of five), and di
138 HI) agar, and a 2.0 McFarland inoculum; (ii) Etest glycopeptide resistance detection (GRD) using vanc
139 Institute broth microdilution method and the Etest GRD (glycopeptide resistance detection) method (bi
141 es and determined the prevalence of hVISA by Etest GRD and population analysis profile-area under the
144 romethod was 57% sensitive and 96% specific, Etest GRD was 57% sensitive and 97% specific, and BHI sc
149 synergy test, and the metallo-beta-lactamase Etest, had specificities of >90% for detecting carbapene
155 cin MIC results obtained by Microscan and by Etest in Staphylococcus aureus and enterococci and found
157 range of clinical MICs, reexamination of the Etest interpretation of susceptible and nonsusceptible c
163 he V-MIC (Etest) and the frequency of hVISA (Etest macromethod) for all MRSA blood isolates saved ove
168 ystem [EARSS]), and the macrodilution method Etest (MET) (EARSS), with population analysis profile-ar
170 he differences in the penicillin MICs by the Etest method and the difficulties of reading the Etest r
171 isolates without the need for MHT, while the Etest method characterized many KPC-Kp isolates as susce
172 microdilution testing and the results of the Etest method for any of the antimicrobial agents tested;
175 l methods were easy to perform; however, the Etest method required more expertise to interpret the re
177 es is required to confirm the ability of the Etest method to detect voriconazole and posaconazole res
186 id, susceptibility rates determined with the Etest method were 67.3% and 52.3% for minocycline, 21.5%
192 omycin and clindamycin susceptibilities with Etest methodology among 546 group A streptococcal isolat
194 rors were similar for the disk diffusion and Etest methods with 0.4 and 0.1%, respectively, very majo
198 this study, we evaluated the performance of Etest MEV (bioMerieux, Marcy l'Etoile, France) compared
202 Susceptibility Testing (EUCAST) breakpoints, Etest MEV performance with clinical (16 MEV resistant) a
209 lation was acceptable for Mucoromycotina but Etest MIC values were consistently lower for Aspergillus
212 EAs between the reference BMD and BMD30, Etest, MicroScan Prompt, and MicroScan turbidity were 63
213 tained with six commercial MIC test systems (Etest, MicroScan, Phoenix, Sensititre, Vitek Legacy, and
214 was lower between reference posaconazole and Etest MICs (94 to 97%) and by both methods with amphoter
216 Overall, the agreement between caspofungin Etest MICs and broth dilution values was higher with MEC
220 lus spp., the agreement between itraconazole Etest MICs read at 24 h and reference microdilution MICs
221 annii, although for most evaluated pathogens Etest MICs trended one doubling-dilution higher than BMD
232 tories (r = 0.86 to 0.88), with 95.3% of the Etest MICs within a +/-1 log(2) dilution of the BMD MIC
234 performed in vitro susceptibility testing by Etest of four carbapenems for M. abscessus isolates.
237 B. pertussis can be simplified by using the Etest or disk diffusion on RL-C to screen for erythromyc
238 In summary, daptomycin MICs generated by the Etest or JustOne method generally agreed within 1 diluti
240 ear 4 (2004 to 2005) was demonstrated by the Etest (P < 0.00007) but not by broth microdilution.
241 rim-sulfamethoxazole results were lower with Etest, particularly when the direct suspension method wa
243 mycin susceptibility were evaluated by using Etest performed prospectively on isolates in routine cli
244 ll categorical agreement levels for VITEK 2, Etest, Phoenix, disk diffusion, and VITEK were 93.0%, 90
245 entrations higher by all AST methods, except Etest, potentially impacting definitive antimicrobial th
246 th in vivo outcome of both microdilution and Etest procedures may detect more-relevant testing condit
248 methods were useful for tigecycline testing; Etest provided a conservative estimate of polymyxin B su
259 and the within-2-log2 general agreement, the Etest results produced slightly lower MICs than the agar
260 t method and the difficulties of reading the Etest results through the glass of a biological safety c
271 ance); the MicroScan and Phoenix systems and Etest tended to categorize susceptible strains as VISA;
272 between Etest and the reference method, the Etest tended to give lower values with both fluconazole
273 between Etest and the reference method, the Etest tended to give lower values with voriconazole and
274 ratories tested 26 diverse strains and found Etest to be reliable for testing antimicrobial agents us
275 acid disk test and the cefotetan-cloxacillin Etest to identify organisms with AmpC beta-lactamase pro
276 ng systems (MicroScan, Vitek 2, Phoenix, and Etest) to detect vancomycin MIC values of </=1 to >/=2 i
279 ntaining 20% horse blood (reference method), Etest using BGA and Regan-Lowe agar without cephalexin (
280 a subset of 314 isolates were also tested by Etest using Casitone agar (CAS) and antibiotic medium 3
284 ls of agreement between broth microdilution, Etest, Vitek 2, Sensititre, and MicroScan methods to acc
290 solates tested were inhibited, determined by Etest, was 32 microgram/ml versus >256 microgram/ml in 7
291 s, measured by broth microdilution (BMD) and Etest, was prospectively assessed for 10 methicillin-res
293 , the results for penicillin obtained by the Etest were 1 to 9 dilutions lower than those obtained by
294 MEs and 28 mEs), and those for MicroScan and Etest were 99.5% each (19 and 13 mEs, respectively).
295 (VMEs) (i.e., false susceptibility) for the Etest were found in 47 to 53% of the resistant isolates,
299 rom a distributed surveillance that utilized Etest yielded a tigecycline activity profile that varied